Tenax Therapeutics, Inc. (TENX) SEC Filing 10-Q Quarterly Report for the period ending Thursday, March 31, 2022

SEC Filings

TENX Quarterly Reports

Tenax Therapeutics, Inc.

CIK: 34956 Ticker: TENX
Cover - shares
3 Months Ended
Mar. 31, 2022
May 12, 2022
Cover [Abstract]  
Entity Registrant NameTENAX THERAPEUTICS, INC. 
Entity Central Index Key0000034956 
Document Type10-Q 
Amendment Flagfalse 
Current Fiscal Year End Date--12-31 
Entity Small Businesstrue 
Entity Shell Companyfalse 
Entity Emerging Growth Companyfalse 
Entity Current Reporting StatusYes 
Document Period End DateMar. 31, 2022 
Entity Filer CategoryNon-accelerated Filer 
Document Fiscal Period FocusQ1 
Document Fiscal Year Focus2022 
Entity Common Stock Shares Outstanding 25,206,914
Document Quarterly Reporttrue 
Document Transition Reportfalse 
Entity File Number001-34600 
Entity Incorporation State Country CodeDE 
Entity Tax Identification Number26-2593535 
Entity Interactive Data CurrentYes 
Entity Address Address Line 1ONE Copley Parkway 
Entity Address Address Line 2Suite 490 
Entity Address City Or TownMorrisville 
Entity Address State Or ProvinceNC 
Entity Address Postal Zip Code27560 
City Area Code919 
Local Phone Number855-2100 
Security 12b TitleCommon Stock, $0.0001 par value per share 
Trading SymbolTENX 
Security Exchange NameNASDAQ 

View differences made from one quarter to another to evaluate Tenax Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Tenax Therapeutics, Inc..


Assess how Tenax Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Tenax Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools


Learn More
Bullish Bearish Neutral
Filter Sentiment:
Filter Category:
Filter Subcategory:
Cash Flow
Inside Tenax Therapeutics, Inc.'s 10-Q Quarterly Report:

Material Contracts, Statements, Certifications & more

Tenax Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: TENX
CIK: 34956
Form Type: 10-Q Quarterly Report
Accession Number: 0001654954-22-006980
Submitted to the SEC: Mon May 16 2022 4:33:18 PM EST
Accepted by the SEC: Mon May 16 2022
Period: Thursday, March 31, 2022
Industry: Commercial Physical And Biological Research

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: